Overview
My clinical activities focus upon general, preventive, and acute care cardiology. I round regularly on the inpatient general cardiology and coronary care unit (CCU) services and i have a particular interest in the treatment and management of patients with acute myocardial infarction and cardiogenic shock. In my outpatient clinic, I care for patients with a variety of cardiovascular conditions include chronic coronary artery disease, hypertension, hyperlipidemia, atrial fibrillation, congestive heart failure, aortic aneurysms, and peripheral arterial disease. In this setting, I have a particular interest in cardiovascular risk factor modification and long-term treatment strategies to mitigate the risk of future cardiovascular events.
My research activities at the Duke Clinical Research Institute focus upon the coordination and leadership of randomized clinical trials evaluating new therapies for a variety of cardiovascular conditions (acute myocardial infarction, hyperlipidemia, coronary stent placement, peripheral arterial disease, and coronary artery disease) as well as observational registries that evaluate the same disease conditions.
My research activities at the Duke Clinical Research Institute focus upon the coordination and leadership of randomized clinical trials evaluating new therapies for a variety of cardiovascular conditions (acute myocardial infarction, hyperlipidemia, coronary stent placement, peripheral arterial disease, and coronary artery disease) as well as observational registries that evaluate the same disease conditions.
Current Appointments & Affiliations
Adjunct Professor in the Department of Medicine
·
2020 - Present
Medicine, Cardiology,
Medicine
Recent Publications
Contribution of Clinical Trial Event Data by Data Source: A Prespecified Analysis of the ADAPTABLE Randomized Clinical Trial.
Journal Article JAMA Cardiol · September 1, 2024 IMPORTANCE: Pragmatic randomized clinical trials (RCTs) often use multiple data sources to examine clinical events, but the relative contribution of data sources to clinical end-point rates is understudied. OBJECTIVE: To assess the contribution of data sou ... Full text Link to item CiteAge and Aspirin Dosing in Secondary Prevention of Atherosclerotic Cardiovascular Disease.
Journal Article J Am Heart Assoc · February 20, 2024 BACKGROUND: In patients with atherosclerotic cardiovascular disease, increasing age is concurrently associated with higher risks of ischemic and bleeding events. The objectives are to determine the impact of aspirin dose on clinical outcomes according to a ... Full text Link to item CiteComparative Effectiveness of Aspirin Dosing in Cardiovascular Disease and Diabetes Mellitus: A Subgroup Analysis of the ADAPTABLE Trial.
Journal Article Diabetes Care · January 1, 2024 OBJECTIVE: Patients with diabetes mellitus (DM) and concomitant atherosclerotic cardiovascular disease (ASCVD) must be on the most effective dose of aspirin to mitigate risk of future adverse cardiovascular events. RESEARCH DESIGN AND METHODS: ADAPTABLE, a ... Full text Link to item CiteRecent Grants
ADAPTABLE Supplement
Clinical TrialPrincipal Investigator · Awarded by Patient-Centered Outcomes Research Institute · 2015 - 2023Evaluating fitness-for-use of Electronic Health Records in Clinical Research
ResearchCo Investigator · Awarded by Food and Drug Administration · 2019 - 2022Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE)
Clinical TrialPrincipal Investigator · Awarded by Patient-Centered Outcomes Research Institute · 2015 - 2020View All Grants
Education, Training & Certifications
Duke University ·
1993
M.D.